Sold as Cefotan, Cefotan In Plastic Container, Cefotetan And Dextrose In Duplex Container. Every FDA application for this active ingredient: 3 branded and 5 generic.
As of Nov 16, 2026, FDA lists 8 applications for Cefotetan Disodium (sold as Cefotan, Cefotan In Plastic Container, Cefotetan And Dextrose In Duplex Container), first approved Dec 27, 1985, with 1 new use approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Cefotetan | Part D | $9K | New | 0 |
| Study | Phase | Status | Posted |
|---|---|---|---|
| Cefotetan Therapy for Escherichia Coli InfectionsE Coli Infection, ESBL Producing E.Coli · Oregon Health and Science University | Phase 2 | Recruiting | Jan 6, 2026 |
| Dec 27, 1985 | CefotanNDA 50588 · New molecular entity | Pai Holdings Pharm | 17 | Marketed |
| Apr 29, 1993 | CefotanANDA 63293 | Teligent | 3 | Discontinued |
| Jul 30, 1993 | Cefotan In Plastic ContainerNDA 50694 · New formulation or manufacturer | Pai Holdings Pharm | 2 | Discontinued |
| Aug 9, 2007 | CefotetanANDA 65374 | Fresenius Kabi USA | 2 | Marketed |
| Aug 9, 2007 | CefotetanANDA 65375 | Fresenius Kabi USA | 1 | Discontinued |
| Aug 9, 2007 | Cefotetan And Dextrose In Duplex ContainerNDA 65430 | B Braun | 2 | Discontinued |
| Oct 26, 2011 | CefotetanANDA 91030 | West-Ward Pharm Corp | 0 | Discontinued |
| Oct 26, 2011 | CefotetanANDA 91031 | Hikma | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA